Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma

Lung Cancer

Volumn 82, Issue 2, 2013, Pages 282-287

  Iuchi, T ^a   Shingyoji, M ^a   Sakaida, T ^a   Hatano, K ^a   Nagano, O ^b   Itakura, M ^a   Kageyama, H ^a   Yokoi, S ^a   Hasegawa, Y ^a   Kawasaki, K ^a   Iizasa, T ^a  

^a CHIBA CANCER CENTER   (Japan)

^b Chiba Cardiovascular Center   (Japan)

Author keywords

EGFR mutation; Gefitinib; Lung cancer; Metastatic brain tumors; Response rate; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB;

ADULT; ARTICLE; BILIARY TRACT DISEASE; BRAIN METASTASIS; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; COGNITION; DRUG EFFICACY; FEMALE; GENE MUTATION; HUMAN; LIVER DISEASE; LIVER DYSFUNCTION; LUNG ADENOCARCINOMA; MALE; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN DISEASE; SKIN TOXICITY; SMOKING; TUMOR GROWTH;

EGFR MUTATION; GEFITINIB; LUNG CANCER; METASTATIC BRAIN TUMORS; RESPONSE RATE; SURVIVAL;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN NEOPLASMS; EXONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS; TREATMENT OUTCOME;

EID: 84887023536     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.08.016     Document Type: Article

References (20)

1. Sørensen J.B., Hansen H.H., Hansen M., Dombernowsky P. Brain metastases in adenocarcinoma of the lung: frequency, risk groups, and prognosis. J Clin Oncol 1988, 6:1474-1480.
2. Regine W.F., Huhn J.L., Patchell R.A., St Clair W.H., Strottmann J., Meigooni A., et al. Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases: results and implications. Int J Radiat Oncol Biol Phys 2002, 52:333-338.
3. Kocher M., Soffietti R., Abacioglu U., Villà S., Fauchon F., Baumert B.G., et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011, 29:134-141.
4. Sperduto P.W., Chao S.T., Sneed P.K., Luo X., Suh J., Roberge D., et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 2010, 77:655-661.
5. Tsao M.N., Rades K., Wirth A., Lo S.S., Danielson B.L., Gaspar L.E., et al. Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2012, 2:210-225.
6. Aoyama H., Tago M., Kato N., Toyoda T., Kenjyo M., Hirota S., et al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys 2007, 68:1388-1395.
7. Meyers C.A., Wefel J.S. The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts or sensitivity [Editorial]. J Clin Oncol 2003, 21:3557-3558.
8. Chang E.L., Wefel J.S., Hess K.R., Allen P.K., Lang F.F., Kornguth D.G., et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomized controlled trial. Lancet Oncol 2009, 10:1037-1044.
9. Moscetti L., Nelli F., Felici A., Rinaldi M., De Santis S., D'Auria G., et al. Up-front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases. Cancer 2007, 109:274-281.
10. Lee D.H., Han J.Y., Kim H.T., Yoon S.J., Pyo H.R., Cho K.H., et al. Primary chemotherapy for newly diagnosed non-small cell lung cancer patients with synchronous brain metastases compared with whole-brain radiotherapy administered first: result of a randomized pilot study. Cancer 2008, 113:143-149.
11. European Organization for Research and Treatment of Cancer: Common Toxicity Criteria (CTC). http://www.eortc.be/services/doc/ctc/default.htm.
12. Agarwal S., Sane R., Gallardo J.L., Ohlfest J.R., Elmquist W.F. Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux. J Pharmacol Exp Ther 2010, 334:147-155.
13. Welsh J.W., Komaki R., Amini A., Munsell M.F., Unger W., Allen P.K., et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 2013, 31:895-902.
14. Ceresoli G.L., Cappuzzo F., Gregorc V., Bartolini S., Crinò L., Villa E. Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial. Ann Oncol 2004, 15:1042-1047.
15. Kim J.E., Lee D.H., Choi Y., Yoon D.H., Kim S.W., Suh C., et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. Lung Cancer 2009, 65:351-354.
16. Riely G.J., Pao W., Pham D., Li A.R., Rizvi N., Venkatraman E.S., et al. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 2006, 12:839-844.
17. Jackman D.M., Yeap B.Y., Sequist L.V., Linderman N., Homes A.J., Joshi V.A., et al. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res 2006, 12:3908-3914.
18. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009, 361:958-967.
19. Kalikaki A., Koutsopoulos A., Trypaki M., Souglakos J., Stathopoulos E., Georgoulias V., et al. Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer 2008, 99:923-929.
20. Gow C.H., Chang Y.L., Hsu Y.C., Tsai M.F., Wu C.T., Yu C.J., et al. Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol 2009, 20:696-702.